Neurocrine (NBIX) Q2 2026 earnings review
Blockbuster Launches Power a Multi-Product Transformation
Neurocrine delivered a standout second quarter, completely shifting its narrative from a single-product company to a diversified rare disease powerhouse. Total revenue surged 39% year-over-year to $959 million. While the core INGREZZA franchise grew a healthy 15%, the real story is the explosive diversification: CRENESSITY reached $184 million in just its second full quarter, and the newly acquired VYKAT XR added $54 million. However, this aggressive expansion comes at a steep price. Management significantly raised full-year guidance for operating expenses to support the Soleno Therapeutics integration and expanded sales forces, meaning near-term GAAP profitability will be weighed down by strategic scaling.
🐂 Bull Case
With 247% year-over-year growth and $184 million in Q2 sales, CRENESSITY is seeing spectacular adoption. The ~80% reimbursement rate proves the clinical value proposition is resonating with payers, justifying the recent sales force expansion.
Despite persistent fears of pricing pressures and future IRA impacts, management raised FY26 INGREZZA guidance to a midpoint of $2.85 billion. Strong double-digit volume growth continues to outpace pricing headwinds.
🐻 Bear Case
The cost of growth is steep. Full-year GAAP SG&A guidance was hiked by $200 million (at the midpoint). While revenue is scaling, massive commercial investments are suppressing near-term margin expansion.
The $2.9 billion acquisition of Soleno depleted cash reserves from $2.5 billion to $482 million. Management must flawlessly execute the VYKAT XR launch to justify the premium paid and rebuild the balance sheet.
⚖️ Verdict: 🟢
Bullish. The successful transition away from an INGREZZA-only story is remarkable. The top-line momentum from CRENESSITY and VYKAT XR provides a massive growth runway, even if operating expenses are currently eating into GAAP margins.
Key Themes
CRENESSITY's Adoption Trajectory Accelerates
CRENESSITY is defying typical orphan drug launch curves. Q2 revenue of $184 million represents a sequential acceleration of 20% over Q1 2026 ($153M). Management cited strong patient demand and an ~80% reimbursement rate for dispensed prescriptions, indicating minimal friction at the payer level. This validates the company's aggressive decision to expand the endocrinology sales force last year.
The Heavy Toll of Integration on Operating Expenses
Scaling a multi-product portfolio is proving expensive. The midpoint of FY26 GAAP SG&A guidance was raised from $1.38 billion to $1.58 billion. While management points to the addition of Soleno's infrastructure and the buildout of VYKAT XR support, this $200 million structural increase directly offsets much of the top-line upside, delaying meaningful operating margin leverage.
INGREZZA Volume Defeats Pricing Headwinds
Despite historical concerns over gross-to-net pressure from strategic Medicare contracting, INGREZZA generated $716 million in Q2, up 15% year-over-year. Record new patient additions (NRx) highlight that the strategy of trading near-term price for long-term volume is paying off, firmly anchoring the company's cash flow generation.
Cash Position Depleted by M&A
Neurocrine's massive cash hoard has been fully deployed. Total cash, cash equivalents, and marketable securities dropped from $2.54 billion at the end of FY25 to $482 million in Q2 2026. While the company secured a $1.0 billion revolving credit facility for liquidity, the balance sheet flexibility for future mid-sized deals is significantly constrained until cash flow catches up.
Shifting the Schizophrenia Paradigm
Neurocrine is aggressively positioning itself against emerging selective M4 agonists in the schizophrenia space. The company initiated a Phase 2 study for NBI-1117570, a dual M1/M4 agonist. Management's thesis is that while M4 targeting addresses positive symptoms, adding M1 activation is critical for targeting cognitive impairment, potentially offering a more holistic, differentiated treatment profile in a crowded clinical landscape.
VYKAT XR Base Effect Risk
VYKAT XR contributed $54 million in just a partial quarter following the May closing of the Soleno acquisition. While highly impressive, investors must monitor whether this reflects an initial bolus of waitlisted Prader-Willi Syndrome patients rapidly filling prescriptions, which could lead to a sequential deceleration in the back half of the year as the patient pool normalizes.
Other KPIs
Accelerating. Up 78% year-over-year from $166 million in Q2 2025. This metric is crucial because it strips out the heavy stock-based compensation and acquisition-related amortization (which surged due to the Soleno deal). It proves the underlying core business is scaling highly profitably, even as GAAP net income grew at a slower 34% pace.
This unaudited pro-forma figure represents what VYKAT XR would have generated had Neurocrine owned it for the full quarter. At nearly $100M per quarter out of the gate, it validates the $2.9 billion price tag paid for Soleno and cements it as the company's third major growth pillar.
Guidance
Accelerating. Raised from the prior range of $2.7 - $2.8 billion. The new midpoint ($2.85B) implies roughly 13% year-over-year growth from FY25's $2.51B. This reflects confidence in continued volume momentum into the second half of the year.
Accelerating significantly. Raised sharply from $1,375 - $1,400 million. This ~$200M bump reflects the immediate integration costs and commercial expansion required to support the newly acquired VYKAT XR alongside the ongoing CRENESSITY launch.
Accelerating. Raised from $1,200 - $1,250 million. The company is leaning heavily into its late-stage pipeline, fully funding Phase 3 programs for osavampator (MDD) and direclidine (schizophrenia), ensuring a data-rich catalyst path for 2027.
Key Questions
SG&A Baseline vs One-Time Costs
The midpoint for FY26 GAAP SG&A was raised by $200 million. How much of this increase is structural to support the VYKAT XR commercial footprint, versus one-time integration expenses associated with the Soleno acquisition?
VYKAT XR Launch Dynamics
The pro-forma $94 million full-quarter revenue for VYKAT XR is exceptional. How much of this represents a clearing of a pre-existing patient waitlist versus normalized run-rate demand in the Prader-Willi Syndrome market?
Capital Allocation Pause?
With total cash and investments down to $482 million post-acquisition, and the company entering a new $1.0 billion credit facility, are mid-to-large scale business development transactions effectively paused until cash balances are rebuilt?